AAS
NBIX icon

Ameritas Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Ameritas Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$628 – 2633
2025
Q2 		$628 Buy
+5
New +$573 ﹤0.01% 2680
2023
Q2 		– Sell
-5
Closed -$518 – 1824
2023
Q1 		$518 Sell
5
-15,496
-100% -$1.61M ﹤0.01% 2647
2022
Q4 		$1.85M Buy
+15,501
New +$1.82M 0.09% 232

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameritas Advisory Services's NBIX Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 5 shares — an estimated $628 sold.

Ameritas Advisory Services first reported a position in NBIX in Q4 2022 and held it in 3 quarters. The position peaked at $1.85M in Q4 2022. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 5 Neurocrine Biosciences shares in Q3 2025, an estimated $628.
  • Ameritas Advisory Services first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 3 quarters.
  • Ameritas Advisory Services's Neurocrine Biosciences position peaked at $1.85M in Q4 2022.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.